{"success":true,"data":{"pressRelease":{"id":"9701","rtpr_id":"nGNE2SwM5Z","ticker":"ALCLS","exchange":"Euronext Paris","all_tickers":["ALCLS"],"title":"REG-Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting","author":"Globe Newswire","published_at":"2026-04-27T20:30:00.075Z","article_body":"NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”)\n(Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology\ncompany using its pioneering gene editing platform to develop life-saving cell\nand gene therapies, today presents new research on a TALE-based epigenetic\nediting approach, that does not cut or permanently modify the DNA sequence,\nmaking it a potentially safer alternative for genome editing, at the American\nSociety of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on\nMay 11-15, in Boston (MA).\n\nThe data will be presented in a poster:\n\nTitle: TALE-based epigenetic modulators show sustained knock-down of target\ngenes in T-cells and HEPG2 via a high-throughput multiplex screening platform\n\nTranscription activator-like effector-based epigenetic modulators (TALEM) are\nengineered fusion proteins consisting of a TALE DNA-binding domain with\nfunctional domains that mediate epigenetic modifications. These proteins can\nbe precisely guided to a target location in the genome to switch genes on or\noff through a process known as epigenetic editing.\n\nUnlike traditional gene editing tools, this approach does not induce DNA\nbreaks and DNA sequence modifications, making it a potentially safer\nalternative for genome editing.\n\nIn this work, Cellectis developed a high-throughput screening system capable\nof rapidly assembling and testing hundreds of these TALEM, identifying which\ncombinations are most effective at regulating a given gene.\n\nThe results: \n\nThis strategy was used for two distinct genes: one highly expressed in\nhepatocytes (active in liver cells) and another implicated in T-cell\ndysfunction and exhaustion, a key challenge in cancer immunotherapy. In both\ncases, the approach achieved >90% reduction in gene activity, which remained\nstable throughout the study.\n\n“We are excited to present these results at ASGCT, which demonstrate\nCellectis’ ability to apply its gene editing platform into the emerging\nfield of epigenetic editing” said Louisa Mayer, Ph.D., Scientist II and\nSupervisor - Innovation & Gene Editing at Cellectis. “This work shows our\nability to design and identify highly potent epigenetic editors across\ndifferent cell types, thereby enriching our gene‑editing toolbox.”\n\nThe abstract is published on the ASGCT website\n(https://www.globenewswire.com/Tracker?data=Cky8naEA3efB11Ita9CRbCf79epbtxdpP5E0HUN3h_kvZwpERDCcStODBBOZxAFPzLQyiaNt8bkjiZhVEhf29sMJK751FFdDJkWTUquLz9NNBhfNxknyRwYZzpcU5szu).\nThe poster will be available on Cellectis’ website\n(https://www.globenewswire.com/Tracker?data=2yQiL4JxjQq8Z4Ocsvn4qcVWki9A1N3BMP7KwB2cHZYUy2F2TxpCja9bXD9mNX3POy58ZUMNuKcs7QXzlFDGsDBrlzLO21qCvO8rWqLBmmYfKk8tU7i67yhdxu4l8khCRfZM7oedTHXO38ZTZDYtrg==)\non the presentation day, Wednesday May 13, 2026 at 5 pm ET.\n\nAbout Cellectis\nCellectis is a clinical-stage biotechnology company using its pioneering\ngene-editing platform to develop life-saving cell and gene therapies. The\ncompany utilizes an allogeneic approach for CAR T immunotherapies in oncology,\npioneering the concept of off-the-shelf and ready-to-use gene-edited CAR\nT-cells to treat cancer patients, and a platform to develop gene therapies in\nother therapeutic indications. With its in-house manufacturing capabilities,\nCellectis is one of the few end-to-end gene editing companies that controls\nthe cell and gene therapy value chain from start to finish.\n\nCellectis’ headquarters are in Paris, France, with locations in New York and\nRaleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS)\nand on Euronext Growth (ticker: ALCLS). To find out more,\nvisit www.cellectis.com and follow Cellectis on LinkedIn\n(https://www.globenewswire.com/Tracker?data=rbUtlSBJ6EaU3ytTlkhUEjvqNasfz44wq9r_iDKMT8CWBCquPHky8blGBR_-zw-uX-5ZPvNOsJwm3KKhy9paBvXBKoisvskDDVe6fdw6y1iliINLrCq9bM0FtmGgRaGs4L-h3TwNyuOapw_ervxgYA==) and X\n(https://www.globenewswire.com/Tracker?data=KC_0D0lorirk5iOIiVmiwJZ2HxL-bAowD47lVQX20Lt9GWMujE8_uqZCWO-zxclaxjPV6FV8sPHKvU6dU7OjZw==).\n\nCautionary Statement \n\nThis press release contains “forward-looking” statements within the\nmeaning of applicable securities laws, including the Private Securities\nLitigation Reform Act of 1995. Forward-looking statements may be identified by\nwords such as “can,” or “potentially,” or the negative of these and\nsimilar expressions. These forward-looking statements are based on our\nmanagement’s current expectations and assumptions and on information\ncurrently available to management. Forward-looking statements include\nstatements about the potential of our innovation programs. These\nforward-looking statements are subject to significant risks and uncertainties,\nincluding those described in our Annual Report on Form 20-F as amended and\nin our annual financial report (including the management report) for the year\nended December 31, 2025 and subsequent filings Cellectis makes with the\nSecurities Exchange Commission from time to time, which are available on the\nSEC’s website at www.sec.gov, as well as other known and unknown risks and\nuncertainties may adversely affect such forward-looking statements and cause\nour actual results, performance or achievements to be materially different\nfrom those expressed or implied by the forward-looking statements. Except as\nrequired by law, we assume no obligation to update these forward-looking\nstatements publicly, or to update the reasons why actual results could differ\nmaterially from those anticipated in the forward-looking statements, even if\nnew information becomes available in the future.\n\nFor further information on Cellectis, please contact:\n\nMedia contacts:\nPascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14\n33, media@cellectis.com         \n\nPatricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93\n\nInvestor Relations contact:\nArthur Stril, Chief Financial Officer & Chief Business\nOfficer, investors@cellectis.com\n\nAttachment\n*     PRESS RELEASE_ ASGCT\n(https://ml.globenewswire.com/Resource/Download/3c0eb218-da31-4056-9a5f-8df548e7aa08)","article_body_html":"","raw_payload":{"data":{"id":"nGNE2SwM5Z","title":"REG-Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting","author":"Globe Newswire","ticker":"ALCLS","created":"2026-04-27T20:30:00.075Z","tickers":["ALCLS"],"exchange":"Euronext Paris","article_body":"NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”)\n(Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology\ncompany using its pioneering gene editing platform to develop life-saving cell\nand gene therapies, today presents new research on a TALE-based epigenetic\nediting approach, that does not cut or permanently modify the DNA sequence,\nmaking it a potentially safer alternative for genome editing, at the American\nSociety of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on\nMay 11-15, in Boston (MA).\n\nThe data will be presented in a poster:\n\nTitle: TALE-based epigenetic modulators show sustained knock-down of target\ngenes in T-cells and HEPG2 via a high-throughput multiplex screening platform\n\nTranscription activator-like effector-based epigenetic modulators (TALEM) are\nengineered fusion proteins consisting of a TALE DNA-binding domain with\nfunctional domains that mediate epigenetic modifications. These proteins can\nbe precisely guided to a target location in the genome to switch genes on or\noff through a process known as epigenetic editing.\n\nUnlike traditional gene editing tools, this approach does not induce DNA\nbreaks and DNA sequence modifications, making it a potentially safer\nalternative for genome editing.\n\nIn this work, Cellectis developed a high-throughput screening system capable\nof rapidly assembling and testing hundreds of these TALEM, identifying which\ncombinations are most effective at regulating a given gene.\n\nThe results: \n\nThis strategy was used for two distinct genes: one highly expressed in\nhepatocytes (active in liver cells) and another implicated in T-cell\ndysfunction and exhaustion, a key challenge in cancer immunotherapy. In both\ncases, the approach achieved >90% reduction in gene activity, which remained\nstable throughout the study.\n\n“We are excited to present these results at ASGCT, which demonstrate\nCellectis’ ability to apply its gene editing platform into the emerging\nfield of epigenetic editing” said Louisa Mayer, Ph.D., Scientist II and\nSupervisor - Innovation & Gene Editing at Cellectis. “This work shows our\nability to design and identify highly potent epigenetic editors across\ndifferent cell types, thereby enriching our gene‑editing toolbox.”\n\nThe abstract is published on the ASGCT website\n(https://www.globenewswire.com/Tracker?data=Cky8naEA3efB11Ita9CRbCf79epbtxdpP5E0HUN3h_kvZwpERDCcStODBBOZxAFPzLQyiaNt8bkjiZhVEhf29sMJK751FFdDJkWTUquLz9NNBhfNxknyRwYZzpcU5szu).\nThe poster will be available on Cellectis’ website\n(https://www.globenewswire.com/Tracker?data=2yQiL4JxjQq8Z4Ocsvn4qcVWki9A1N3BMP7KwB2cHZYUy2F2TxpCja9bXD9mNX3POy58ZUMNuKcs7QXzlFDGsDBrlzLO21qCvO8rWqLBmmYfKk8tU7i67yhdxu4l8khCRfZM7oedTHXO38ZTZDYtrg==)\non the presentation day, Wednesday May 13, 2026 at 5 pm ET.\n\nAbout Cellectis\nCellectis is a clinical-stage biotechnology company using its pioneering\ngene-editing platform to develop life-saving cell and gene therapies. The\ncompany utilizes an allogeneic approach for CAR T immunotherapies in oncology,\npioneering the concept of off-the-shelf and ready-to-use gene-edited CAR\nT-cells to treat cancer patients, and a platform to develop gene therapies in\nother therapeutic indications. With its in-house manufacturing capabilities,\nCellectis is one of the few end-to-end gene editing companies that controls\nthe cell and gene therapy value chain from start to finish.\n\nCellectis’ headquarters are in Paris, France, with locations in New York and\nRaleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS)\nand on Euronext Growth (ticker: ALCLS). To find out more,\nvisit www.cellectis.com and follow Cellectis on LinkedIn\n(https://www.globenewswire.com/Tracker?data=rbUtlSBJ6EaU3ytTlkhUEjvqNasfz44wq9r_iDKMT8CWBCquPHky8blGBR_-zw-uX-5ZPvNOsJwm3KKhy9paBvXBKoisvskDDVe6fdw6y1iliINLrCq9bM0FtmGgRaGs4L-h3TwNyuOapw_ervxgYA==) and X\n(https://www.globenewswire.com/Tracker?data=KC_0D0lorirk5iOIiVmiwJZ2HxL-bAowD47lVQX20Lt9GWMujE8_uqZCWO-zxclaxjPV6FV8sPHKvU6dU7OjZw==).\n\nCautionary Statement \n\nThis press release contains “forward-looking” statements within the\nmeaning of applicable securities laws, including the Private Securities\nLitigation Reform Act of 1995. Forward-looking statements may be identified by\nwords such as “can,” or “potentially,” or the negative of these and\nsimilar expressions. These forward-looking statements are based on our\nmanagement’s current expectations and assumptions and on information\ncurrently available to management. Forward-looking statements include\nstatements about the potential of our innovation programs. These\nforward-looking statements are subject to significant risks and uncertainties,\nincluding those described in our Annual Report on Form 20-F as amended and\nin our annual financial report (including the management report) for the year\nended December 31, 2025 and subsequent filings Cellectis makes with the\nSecurities Exchange Commission from time to time, which are available on the\nSEC’s website at www.sec.gov, as well as other known and unknown risks and\nuncertainties may adversely affect such forward-looking statements and cause\nour actual results, performance or achievements to be materially different\nfrom those expressed or implied by the forward-looking statements. Except as\nrequired by law, we assume no obligation to update these forward-looking\nstatements publicly, or to update the reasons why actual results could differ\nmaterially from those anticipated in the forward-looking statements, even if\nnew information becomes available in the future.\n\nFor further information on Cellectis, please contact:\n\nMedia contacts:\nPascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14\n33, media@cellectis.com         \n\nPatricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93\n\nInvestor Relations contact:\nArthur Stril, Chief Financial Officer & Chief Business\nOfficer, investors@cellectis.com\n\nAttachment\n*     PRESS RELEASE_ ASGCT\n(https://ml.globenewswire.com/Resource/Download/3c0eb218-da31-4056-9a5f-8df548e7aa08)"},"type":"article","timestamp":"2026-04-27T20:30:00.167645398Z","server_sent_at_ms":1777321800167},"received_at":"2026-04-27T20:30:00.236Z","source_url":null},"analysis":{"id":"7368","press_release_id":"9701","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Cellectis is presenting new research at the ASGCT annual meeting on a TALE-based epigenetic editing platform that can turn genes off without cutting or permanently modifying DNA.\n\nThe study results show that this approach achieved greater than 90% reduction in gene activity in T-cells and liver cells, with the effect remaining stable throughout the study.\n\nBy developing a high-throughput screening system to identify effective protein combinations, Cellectis aims to provide a potentially safer alternative for genome editing in cell and gene therapies.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Pre-clinical data shows >90% gene knockdown using non-cutting epigenetic editors, validating platform safety."},"keyFigures":{"customDimensions":{"cell_types":"T-cells and HEPG2","gene_activity_reduction":">90%"}},"quotedText":"We are excited to present these results at ASGCT, which demonstrate Cellectis’ ability to apply its gene editing platform into the emerging field of epigenetic editing","namedEntities":{"people":[{"name":"Louisa Mayer","role":"Scientist II and Supervisor - Innovation & Gene Editing"},{"name":"Pascalyne Wilson","role":"Director, Communications"},{"name":"Patricia Sosa Navarro","role":"Chief of Staff to the CEO"},{"name":"Arthur Stril","role":"Chief Financial Officer & Chief Business Officer"}],"products":["TALE-based epigenetic editing platform","TALEM"],"companies":[{"name":"Cellectis","ticker":"ALCLS"},{"name":"American Society of Gene and Cell Therapy","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Presentation of pre-clinical platform data at a major industry conference (ASGCT) validates the efficacy (>90% knockdown) and safety profile (non-cutting) of the company's epigenetic editing technology."},"tickerRelevance":{"others":[{"ticker":"CLLS","relevance":"mentioned"}],"primary":"ALCLS"},"globalImportance":20,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small/mid-cap","eventGravity":"pre-clinical platform data presentation","sectorWeight":"biotech"}},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Cellectis is presenting new research at the ASGCT annual meeting on a TALE-based epigenetic editing platform that can turn genes off without cutting or permanently modifying DNA.\n\nThe study results show that this approach achieved greater than 90% reduction in gene activity in T-cells and liver cells, with the effect remaining stable throughout the study.\n\nBy developing a high-throughput screening system to identify effective protein combinations, Cellectis aims to provide a potentially safer alternative for genome editing in cell and gene therapies.","key_figures":{"customDimensions":{"cell_types":"T-cells and HEPG2","gene_activity_reduction":">90%"}},"named_entities":{"people":[{"name":"Louisa Mayer","role":"Scientist II and Supervisor - Innovation & Gene Editing"},{"name":"Pascalyne Wilson","role":"Director, Communications"},{"name":"Patricia Sosa Navarro","role":"Chief of Staff to the CEO"},{"name":"Arthur Stril","role":"Chief Financial Officer & Chief Business Officer"}],"products":["TALE-based epigenetic editing platform","TALEM"],"companies":[{"name":"Cellectis","ticker":"ALCLS"},{"name":"American Society of Gene and Cell Therapy","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:1fc968c3ac7f7ebb","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-04-27T20:53:04.952Z","global_importance":20,"audience_relevance":25,"importance_components":{"tickerTier":"small/mid-cap","eventGravity":"pre-clinical platform data presentation","sectorWeight":"biotech"}},"durationMs":59819,"modelName":"glm-4.7"}}